The Food and Drug Administration on Thursday laid out a proposed new regulatory plan to oversee potentially thousands of laboratory-developed medical tests that the agency contends can be prone to errors.. These diagnostic and other tests are for diseases including cancer, heart disease and bacterial infections. They can also assess how well a given drug will help patients with a certain genetic makeup. For years, the FDA allowed these medical tests to be used as niche products at hospitals and labs largely without agency approval...
  